» Articles » PMID: 25454617

How Does Active Surveillance for Prostate Cancer Affect Quality of Life? A Systematic Review

Overview
Journal Eur Urol
Specialty Urology
Date 2014 Dec 3
PMID 25454617
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Context: The optimal management of screen-detected, localised prostate cancer remains controversial, related to overtreatment issues of screening and the nonrandomised evidence base. Active surveillance (AS) aims to delay or avoid curative therapy but may potentially harm patients' well-being through living with untreated prostate cancer.

Objective: To systematically review the literature on quality of life (QoL) in patients undergoing AS.

Evidence Acquisition: Embase, Medline, Psychinfo, Cochrane Central, Web of Science, and PubMed databases were searched in May 2014 using quality of life, active surveillance, prostate cancer, their synonyms, and targeted manual searches. The psychological dimensions related to health-related QoL (HRQoL) outcomes were anxiety and depression, distress, decisional conflict, and mental health.

Evidence Synthesis: Ten clinical and research-based AS studies worldwide measured HRQoL and related psychological facets in six cross-sectional studies and four cohorts (follow-up: 9-36 mo; published: 2006-2014). Six studies were linked to published AS cohorts. In total, 966 men undergoing AS (mean: 102 per study) were assessed (mean age: 66 yr). AS patients had good overall HRQoL scores, which were comparable or better than those of patients undergoing postradical treatment (comparator group in four studies), men's partners (one study) and population-based data (three studies). Anxiety and depression scores were favourable. Selection bias may be present, as none were randomised comparisons. Decreased psychological well-being may be partly predicted by AS patients' baseline and clinical characteristics.

Conclusions: Patients undergoing AS reported good QoL and did not appear to suffer major negative psychological impacts. Longer follow-up is required as well as investigation into which patients are predisposed to negative impact and leaving AS prematurely.

Patient Summary: We reviewed the published evidence for quality-of-life impact on men with prostate cancer being monitored by active surveillance. The men who were on active surveillance usually reported good levels of well-being and did not appear to suffer major negative psychological impacts. The research findings suggest little presence of anxiety and depression and high overall quality of life related to their disease. However, there are few long-term studies, so more high-quality research is needed to make definitive recommendations.

Citing Articles

Quality of Life Assessment Among Ethnically Diverse Black Prostate Cancer Survivors: A Constructivist Grounded Theory Approach.

Ogunsanya M, Kaninjing E, Ellis T, Bamidele O, Morton D, McIntosh A Res Sq. 2024; .

PMID: 38464107 PMC: 10925397. DOI: 10.21203/rs.3.rs-3941497/v1.


Active surveillance of atypical cartilaginous tumours of bone: short term quality of life measurements.

Deckers C, van Zeijl N, van Hooff M, Veldman-Goossen P, Schreuder H, Dierselhuis E J Orthop Surg Res. 2023; 18(1):208.

PMID: 36922843 PMC: 10018839. DOI: 10.1186/s13018-023-03694-9.


Treatment of localized prostate cancer in elderly patients: the role of partial cryoablation.

Selvaggio O, Finati M, Falagario U, Silecchia G, Recchia M, Checchia A Int Urol Nephrol. 2023; 55(5):1125-1132.

PMID: 36809642 PMC: 10105669. DOI: 10.1007/s11255-023-03519-y.


Patient-Factors Influencing the 2-Year Trajectory of Mental and Physical Health in Prostate Cancer Patients.

Cicchetti A, Noale M, Dordoni P, Noris Chiorda B, De Luca L, Bellardita L Curr Oncol. 2022; 29(11):8244-8260.

PMID: 36354711 PMC: 9689299. DOI: 10.3390/curroncol29110651.


Long-term Health-related Quality of Life in Patients on Active Surveillance for Prostate Cancer: A Systematic Review.

Thompson D, Bensley J, Tempo J, Ehdaie B, Carlsson S, Eastham J Eur Urol Oncol. 2022; 6(1):4-15.

PMID: 36156268 PMC: 9908828. DOI: 10.1016/j.euo.2022.09.001.